Interview: Roberto Bellini, President & CEO, Bellus Health, Canada
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
Bellus Health is a development-focused healthcare company concentrating on products that provide innovative health solutions and address critical unmet medical needs. The Company’s product pipeline and development strategy includes two pharmaceutical drug candidates and one commercial stage nutraceutical product.
The Company’s lead program is KIACTA, a novel drug candidate currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA is partnered with global private equity firm Auven Therapeutics. AA amyloidosis affects approximately 35,000 to 50,000 individuals in the United States, Europe and Japan.
Bellus Health is based in Laval, Quebec and its shares trade under the ticker BLU on the Toronto Stock Exchange.
275 Armand-Frappier Blvd.
Laval,
Quebec
Canada
H7V 4A7
Tel.: (450) 680-4500
Fax: (450) 680-4501
The CEO of Bellus Health outlines his strategy since 2010 to change the focus of the company from Alzheimer’s to a niche disease, AA amyloidosis, as well as the strategic…
At the 350th anniversary of the company, Gaby Murphy, EMD Serono’s managing director, gives an insight into the turning point for the affiliate in 2017 with three new Health Canada…
Investissement Québec (IQ) contributed to the completion of 65 international projects in 2017 and hosts Pfizer, Sanofi, and Merck amongst over 160 IT companies, employing over 5,400 workers. Pierre Gabriel…
Imran Ali, senior manager of the pan-Canadian Pharmaceutical Alliance (pCPA) Office, the body that provides dedicated centralized support to the national negotiating process for drug prices, representing all 14 public…
Taiho Pharmaceutical Co., Ltd. (TPC), Japan, part of Otsuka Holdings, established its Canadian affiliate in 2017. Ross Glover, general manager for Taiho Pharma Canada, has spent the past year tackling…
At the company’s 40th anniversary, Biogen’s Canadian head Marina Vasiliou gives an insight into her priorities as new managing director, her approach to building relationships with all stakeholders in the…
Looking back on his first year as CEO of Organigram, Greg Engel proudly highlights the successful transition of the company from being a low-cost to a high-quality cannabis producer with…
Still in the process of integration, Mallinckrodt is preparing to build its launch structure in Canada. With several innovative products in the pipeline, Robin Hunter, general manager of Canadian operations,…
Boston Scientific’s vice president and general manager Ken Spears shares his thoughts about the potential for Canada to become an early adopter of innovation and to move towards an outcome-based…
Hydropothecary is the leading medicinal cannabis producer in Quebec, founded in 2013 by two brothers-in-law, Sebastien St-Louis and Adam Miron. Terry Lake, former Minister of Health for British Colombia, discusses…
Upon opening an R&D center in Mississauga in 2017, Biolab Pharma Canada, headed by Paulo Wickbold Marques, became the first Brazilian pharmaceutical company to establish an affiliate in Canada. In…
Halo Pharma, a US-based one-stop-shop CDMO (Contract Development and Manufacturing Organization), operates out of a site in Mirabel, close to Montreal, that boasts 30 years of experience in developing and…
Boiron Canada is the sixth largest affiliate of Boiron’s global operations (in terms of sales), and under Daniel Dereser’s leadership, the company intends to change the perception of homeopathic medicine…
See our Cookie Privacy Policy Here